Zoetis (NYSE:ZTS – Free Report) had its target price hoisted by Jefferies Financial Group from $83.00 to $85.00 in a report released on Friday morning.
Other research analysts have also issued reports about the company. Piper Sandler decreased their price objective on Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a report on Monday, August 10th. Stifel Nicolaus lowered their price objective on Zoetis from $85.00 to $80.00 and set a “hold” rating on the stock in a research report on Thursday, August 20th. BTIG Research dropped coverage on Zoetis in a report on Friday, October 30th. They set a “buy” rating and a $200.00 target price for the company. Citigroup reduced their target price on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. Finally, The Goldman Sachs Group began coverage on shares of Zoetis in a research note on Friday, October 16th. They issued a “neutral” rating and a $74.00 price target on the stock. Eight analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $101.25.
View Our Latest Research Report on ZTS
Zoetis Stock Performance
Shares of ZTS stock traded down $2.61 during midday trading on Friday, hitting $79.50. 6,023,502 shares of the company were exchanged, compared to its average volume of 3,857,472. Zoetis has a 52 week low of $68.77 and a 52 week high of $132.49. The firm has a market capitalization of $32.85 billion, a P/E ratio of 13.52, a PEG ratio of 1.23 and a beta of 0.67. The firm’s 50 day moving average price is $75.68 and its two-hundred day moving average price is $92.60. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08.
Zoetis (NYSE:ZTS – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $1.75 earnings per share for the quarter, beating the consensus estimate of $1.51 by $0.24. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The firm had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.30 billion. During the same period in the prior year, the firm earned $1.70 EPS. The business’s revenue was down 1.3% on a year-over-year basis. As a group, equities research analysts anticipate that Zoetis will post 6.15 earnings per share for the current year.
Zoetis Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Friday, October 30th. This represents a $2.12 dividend on an annualized basis and a yield of 2.7%. Zoetis’s dividend payout ratio is currently 34.93%.
Hedge Funds Weigh In On Zoetis
A number of hedge funds have recently added to or reduced their stakes in ZTS. BlackRock Inc. grew its holdings in shares of Zoetis by 10.8% during the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock worth $2,833,453,000 after purchasing an additional 3,845,869 shares in the last quarter. State Street Corp raised its stake in Zoetis by 1.8% in the second quarter. State Street Corp now owns 19,667,723 shares of the company’s stock valued at $1,413,323,000 after purchasing an additional 343,322 shares in the last quarter. Bank of America Corp DE raised its stake in Zoetis by 7.3% in the first quarter. Bank of America Corp DE now owns 4,831,652 shares of the company’s stock valued at $571,150,000 after purchasing an additional 327,313 shares in the last quarter. Deutsche Bank AG raised its stake in Zoetis by 5.8% in the second quarter. Deutsche Bank AG now owns 5,851,737 shares of the company’s stock valued at $420,506,000 after purchasing an additional 319,709 shares in the last quarter. Finally, Van ECK Associates Corp lifted its position in Zoetis by 7.7% during the second quarter. Van ECK Associates Corp now owns 4,252,140 shares of the company’s stock worth $305,559,000 after purchasing an additional 303,395 shares during the period. Institutional investors own 92.80% of the company’s stock.
Key Stories Impacting Zoetis
Here are the key news stories impacting Zoetis this week:
- Positive Sentiment: Adjusted EPS of $1.75 topped the $1.51 consensus, while revenue of $2.39 billion exceeded expectations of $2.30 billion. Zoetis also raised its full-year 2026 profit outlook. Zoetis Lifts Annual Outlook While Braces For Cautious Pet Economy
- Positive Sentiment: Livestock revenue grew 7% to $797 million, helping offset softness in companion-animal products. Jefferies also raised its price target to $85 from $83. Zoetis: 3 Key Takeaways for Long-Term Investors
- Negative Sentiment: Investors appear focused on ongoing pressure in the pet-health business: owners are cutting back on veterinary visits, and Zoetis is taking a cautious view of 2027. Competitive pressures and margin headwinds also weigh on the outlook. Zoetis plans cautiously for 2027 as pet owners cut back on vet visits, shares fall ZTS Q3 2026 deep dive: Competitive pressures and margin headwinds weigh on outlook
- Negative Sentiment: Despite beating estimates, quarterly revenue declined 1.3% year over year, reinforcing concerns that strength in livestock may not fully offset weaker companion-animal demand. Zoetis reports third-quarter results
About Zoetis
Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish.
The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.
Zoetis originated as Pfizer’s animal health business and became an independent public company in 2013.
See Also
- Five stocks we like better than Zoetis
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
